Intervention
Giredestrant
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 19 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
19 shownA Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)NCT07541079 · 2026-08-25
RECRUITINGA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerNCT07100106 · 2025-10-07
RECRUITINGA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerNCT07054190 · 2025-09-09
RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerNCT04802759 · 2021-06-22
RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerNCT03424005 · 2018-03-30
RECRUITINGA Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During TreatmentNCT07827573 · 2026-10-30
NOT_YET_RECRUITINGA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast CancerNCT07214662 · 2026-01-13
TERMINATEDA PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationNCT05708235 · 2024-04-01
ACTIVE_NOT_RECRUITINGA Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerNCT05896566 · 2024-01-23
COMPLETEDA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11
ACTIVE_NOT_RECRUITINGPreoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%NCT05659563 · 2023-07-20
COMPLETEDA Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)NCT05306340 · 2022-08-03
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)NCT05296798 · 2022-07-18
ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)NCT04961996 · 2021-08-27
ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)NCT04576455 · 2020-11-27
ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)NCT04546009 · 2020-10-09
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)NCT04436744 · 2020-09-04
COMPLETEDA Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast CancerNCT03916744 · 2019-07-26
COMPLETEDExpanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast CancerNCT07643831
AVAILABLECommon conditions
Breast Cancer7Early Breast Cancer4Breast Cancer, Early-Onset1ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer1Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer1Estrogen Receptor-Positive Breast Cancer1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer1Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer1Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer1HER2-Negative Breast Cancer1Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer1Locally Advanced or Metastatic Breast Cancer1Metastatic Breast Cancer1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING7
RECRUITING5
COMPLETED4
AVAILABLE1
NOT_YET_RECRUITING1
TERMINATED1
Phase mix
PHASE29
PHASE37
PHASE15
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.